Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S H Scharla

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Bone and Mineral|September 1, 1989
1,25-Dihydroxyvitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO)U G Lempert, H W Minne, B Albrecht, et al.
Archives of Oral Biology|August 1, 1992
Transforming growth factor-beta 1 mRNA in neonatal ovine molars visualized by in situ hybridization: potential role for the stratum intermediumS Jepsen, P Schiltz, D D Strong, et al.
Bone and Mineral|May 1, 1989
The hypercalcemic Walker carcinosarcoma 256 of the rat causes an increase in serum 1,25-dihydroxyvitamin D3S H Scharla, H W Minne, C Oswald, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1996
Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based studyS H Scharla, C Scheidt-Nave, G Leidig, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 15, 1991
[PTH-related protein (PTHrP) in serum of patients with tumor hypercalcemia]S H Scharla, M Pecherstorfer, U G Lempert, et al.
Experimental and Clinical Endocrinology|January 1, 1994
Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)S H Scharla, H W Minne, U G Lempert, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1993
1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivoS H Scharla, D D Strong, C Rosen, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 1, 1991
Osteolytic activity of Walker carcinosarcoma 256 is due to parathyroid hormone-related protein (PTHrP)S H Scharla, H W Minne, U G Lempert, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1990
Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3S H Scharla, H W Minne, S Waibel-Treber, et al.
Bone and Mineral|August 1, 1993
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemiaC Wüster, K H Schöter, D Thiébaud, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Bone and Mineral|September 1, 1989
1,25-Dihydroxyvitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO)U G Lempert, H W Minne, B Albrecht, et al.
Archives of Oral Biology|August 1, 1992
Transforming growth factor-beta 1 mRNA in neonatal ovine molars visualized by in situ hybridization: potential role for the stratum intermediumS Jepsen, P Schiltz, D D Strong, et al.
Bone and Mineral|May 1, 1989
The hypercalcemic Walker carcinosarcoma 256 of the rat causes an increase in serum 1,25-dihydroxyvitamin D3S H Scharla, H W Minne, C Oswald, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1996
Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based studyS H Scharla, C Scheidt-Nave, G Leidig, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 15, 1991
[PTH-related protein (PTHrP) in serum of patients with tumor hypercalcemia]S H Scharla, M Pecherstorfer, U G Lempert, et al.
Experimental and Clinical Endocrinology|January 1, 1994
Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)S H Scharla, H W Minne, U G Lempert, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1993
1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivoS H Scharla, D D Strong, C Rosen, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 1, 1991
Osteolytic activity of Walker carcinosarcoma 256 is due to parathyroid hormone-related protein (PTHrP)S H Scharla, H W Minne, U G Lempert, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1990
Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3S H Scharla, H W Minne, S Waibel-Treber, et al.
Bone and Mineral|August 1, 1993
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemiaC Wüster, K H Schöter, D Thiébaud, et al.
Pageof 3